BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25446851)

  • 1. Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3.
    Schaupp CM; White CC; Merrill GF; Kavanagh TJ
    Chem Biol Interact; 2015 Jun; 234():154-61. PubMed ID: 25446851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.
    Breysse DH; Boone RM; Long CM; Merrill ME; Schaupp CM; White CC; Kavanagh TJ; Schmidt EE; Merrill GF
    Drug Metab Dispos; 2020 Mar; 48(3):187-197. PubMed ID: 31955137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism.
    Zhou F; Hao G; Zhang J; Zheng Y; Wu X; Hao K; Niu F; Luo D; Sun Y; Wu L; Ye W; Wang G
    Br J Pharmacol; 2015 Dec; 172(23):5690-703. PubMed ID: 25363561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
    Jo A; Choi TG; Jo YH; Jyothi KR; Nguyen MN; Kim JH; Lim S; Shahid M; Akter S; Lee S; Lee KH; Kim W; Cho H; Lee J; Shokat KM; Yoon KS; Kang I; Ha J; Kim SS
    Antioxid Redox Signal; 2017 Jan; 26(2):70-83. PubMed ID: 27357096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
    Fan L; Goh BC; Wong CI; Sukri N; Lim SE; Tan SH; Guo JY; Lim R; Yap HL; Khoo YM; Iau P; Lee HS; Lee SC
    Pharmacogenet Genomics; 2008 Jul; 18(7):621-31. PubMed ID: 18551042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/- mice.
    Freeland MM; Angulo J; Davis AL; Flook AM; Garcia BL; King NA; Mangibin SK; Paul KM; Prosser ME; Sata N; Bentley JL; Olson LE
    Anticancer Drugs; 2012 Jul; 23(6):584-9. PubMed ID: 22343424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of human carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells.
    Ebert B; Kisiela M; Malátková P; El-Hawari Y; Maser E
    Biochemistry; 2010 Oct; 49(39):8499-511. PubMed ID: 20806931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
    Lal S; Sandanaraj E; Wong ZW; Ang PC; Wong NS; Lee EJ; Chowbay B
    Cancer Sci; 2008 Oct; 99(10):2045-54. PubMed ID: 19016765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
    Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
    Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the role of the amino acid residue at position 230 for catalysis in monomeric carbonyl reductase 3.
    Miura T; Itoh Y; Takada M; Tsutsui H; Yukimura T; Nishinaka T; Terada T
    Chem Biol Interact; 2009 Mar; 178(1-3):211-4. PubMed ID: 18983987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
    Kassner N; Huse K; Martin HJ; Gödtel-Armbrust U; Metzger A; Meineke I; Brockmöller J; Klein K; Zanger UM; Maser E; Wojnowski L
    Drug Metab Dispos; 2008 Oct; 36(10):2113-20. PubMed ID: 18635746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
    Blanco JG; Leisenring WM; Gonzalez-Covarrubias VM; Kawashima TI; Davies SM; Relling MV; Robison LL; Sklar CA; Stovall M; Bhatia S
    Cancer; 2008 Jun; 112(12):2789-95. PubMed ID: 18457324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.
    Olson LE; Bedja D; Alvey SJ; Cardounel AJ; Gabrielson KL; Reeves RH
    Cancer Res; 2003 Oct; 63(20):6602-6. PubMed ID: 14583452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis.
    El-Hawari Y; Favia AD; Pilka ES; Kisiela M; Oppermann U; Martin HJ; Maser E
    Chem Biol Interact; 2009 Mar; 178(1-3):234-41. PubMed ID: 19061875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression.
    Zhang J; Blanco JG
    Pharm Res; 2009 Sep; 26(9):2209-15. PubMed ID: 19590938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1.
    Miura T; Nagai K; Kaneshiro S; Taketomi A; Nakabayashi T; Konishi H; Nishinaka T; Terada T
    Drug Metab Lett; 2017 Nov; 11(1):48-52. PubMed ID: 28332451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
    Blanco JG; Sun CL; Landier W; Chen L; Esparza-Duran D; Leisenring W; Mays A; Friedman DL; Ginsberg JP; Hudson MM; Neglia JP; Oeffinger KC; Ritchey AK; Villaluna D; Relling MV; Bhatia S
    J Clin Oncol; 2012 May; 30(13):1415-21. PubMed ID: 22124095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
    Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
    J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of the substrate-binding loop region of human monomeric carbonyl reductases in catalysis and coenzyme binding.
    Miura T; Nishinaka T; Terada T
    Life Sci; 2009 Aug; 85(7-8):303-8. PubMed ID: 19555696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3.
    Staab CA; Hartmanová T; El-Hawari Y; Ebert B; Kisiela M; Wsol V; Martin HJ; Maser E
    Chem Biol Interact; 2011 May; 191(1-3):95-103. PubMed ID: 21256830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.